Scorr-Insert
X

Find Novel Psychiatry/Psychology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            National Institute on Drug Abuse

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: CaaMTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 07, 2020

            Details:

            The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aloradine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2020

            Details:

            VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cleveland Clinic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 20, 2020

            Details:

            The MOU singed between the companies include, production of psilocybin and like molecules used in combination with psychotherapy for the treatment of depression and addiction, and two other molecule.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ondansetron

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 26, 2020

            Details:

            AD04 is indicated for people that are positive for select genotypes identified using the Company's propriety companion genetic test.

            NineteenGale Therapeutics

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoid-based product

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Cyclica

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 19, 2020

            Details:

            Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first-in-class proteome screening platform.

            NYU Grossman School of Medicine

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Psilocybin was associated with enduring antianxiety and antidepressant effects in approximately 60 percent to 80 percent of participants.